MODELING AND SIMULATION BASED EVIDENCE OF CLINICAL ACTIVITY FOR IPILIMUMAB, A NOVEL ANTI-CTLA-4 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED MELANOMA
CLINICAL PHARMACOLOGY & THERAPEUTICS（2009）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined